NCT00731822View on ClinicalTrials.gov

A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GW685698/GW642444

GW685698/GW642444

Trial Locations (9)

1337

GSK Investigational Site, Sandvika

1606

GSK Investigational Site, Fredrikstad

2408

GSK Investigational Site, Elverum

5053

GSK Investigational Site, Bergen

7030

GSK Investigational Site, Trondheim

SE-413 45

GSK Investigational Site, Gothenburg

SE-971 89

GSK Investigational Site, Luleå

SE-221 85

GSK Investigational Site, Lund

SE-118 83

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00731822 - A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter